Brii Biosciences Limited (BRIBF)
OTCMKTS · Delayed Price · Currency is USD
0.2406
+0.0094 (4.07%)
At close: Aug 1, 2025
Brii Biosciences Revenue
Brii Biosciences had revenue of 993.00K CNY in the half year ending June 30, 2025, a decrease of -97.52%. This brings the company's revenue in the last twelve months to 28.77M, down -25.03% year-over-year. In the year 2024, Brii Biosciences had annual revenue of 49.94M, down -10.65%.
Revenue (ttm)
28.77M CNY
Revenue Growth
-25.03%
P/S Ratio
47.88
Revenue / Employee
293.61K CNY
Employees
98
Market Cap
192.32M USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 49.94M | -5.96M | -10.65% |
Dec 31, 2023 | 55.89M | -66.39M | -54.29% |
Dec 31, 2022 | 122.28M | 29.74M | 32.13% |
Dec 31, 2021 | 92.54M | 10.32M | 12.56% |
Dec 31, 2020 | 82.22M | 62.02M | 307.10% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
AMJ Global Technology | 39.00 |
Brii Biosciences News
- 24 days ago - Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results - PRNewsWire
- 2 months ago - Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China - PRNewsWire
- 4 months ago - Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss - PRNewsWire
- 6 months ago - Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification - PRNewsWire
- 9 months ago - Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study - PRNewsWire
- 10 months ago - Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA - PRNewsWire
- 1 year ago - Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024 - PRNewsWire
- 1 year ago - Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer - PRNewsWire